Aligos Therapeutics Inc. (ALGS) Misses Q4 EPS by 191c Mar 5, 2026 04:02PM
H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS) Jan 23, 2026 06:52AM
UBS Starts Aligos Therapeutics Inc. (ALGS) at Buy Jan 7, 2026 12:38AM
Aligos presents drug combination data at hepatitis conference Dec 11, 2025 08:04AM
Aligos gets USAN approval for pevifoscorvir sodium drug name Oct 16, 2025 08:34AM


Sep 19, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)
Aug 20, 2025 08:31AM Aligos appoints Ramón Polo as head of global regulatory affairs
Aug 18, 2025 06:39AM H.C. Wainwright Assumes Aligos Therapeutics Inc. (ALGS) at Buy
Aug 6, 2025 06:26PM Aligos Therapeutics Inc. (ALGS) Misses Q2 EPS by 153c
May 8, 2025 08:06AM Aligos Therapeutics (ALGS) Presents Positive Data at the EASL Congress 2025
Mar 27, 2025 04:12PM Aligos Therapeutics Inc. (ALGS) Files for 6.25M Share Offering by Selling Stockholders
Mar 12, 2025 06:41AM Aligos Therapeutics Inc. (ALGS) PT Lowered to $70 at H.C. Wainwright
Mar 10, 2025 04:27PM Aligos Therapeutics Inc. (ALGS) Misses Q4 EPS by 1308c
Feb 12, 2025 07:00AM Aligos Therapeutics Inc. (ALGS) Announces $105M Private Placement
Nov 19, 2024 01:31PM Aligos Therapeutics (ALGS) Presents Positive Data at The Liver Meeting
Nov 6, 2024 05:10PM Aligos Therapeutics, Inc. (ALGS) Misses Q3 EPS by 290c
Oct 1, 2024 08:02AM Aligos Therapeutics Inc. (ALGS) Appoints David Perry as Vice President of Business Development
Sep 24, 2024 08:02AM Aligos Therapeutics (ALGS) Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Sep 24, 2024 07:52AM Piper Sandler Reiterates Overweight Rating on Aligos Therapeutics Inc. (ALGS)
Sep 20, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Aligos Therapeutics Inc. (ALGS)
Sep 19, 2024 08:00AM Aligos Therapeutics Inc. (ALGS) Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
Sep 18, 2024 05:02PM Aligos Therapeutics Inc. (ALGS) to Report Data from Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
Sep 12, 2024 07:40AM Piper Sandler Reiterates Overweight Rating on Aligos Therapeutics Inc. (ALGS)
Aug 19, 2024 06:13AM H.C. Wainwright Starts Aligos Therapeutics Inc. (ALGS) at Buy
Aug 6, 2024 05:05PM Aligos Therapeutics, Inc. (ALGS) Tops Q2 EPS by 19c
Jul 19, 2024 02:34PM Piper Sandler Reiterates Overweight Rating on Aligos Therapeutics Inc. (ALGS)